Rosalind Franklin University Secures $747K NCI Grant to Decode Pancreatic Cancer Muscle Wasting
Event summary
- Rosalind Franklin University awarded $747K NCI grant for 3-year study on pancreatic cancer cachexia
- Research focuses on epigenetic reprogramming and liver metabolism in muscle wasting
- PDAC accounts for 90% of pancreatic cancers, with rising incidence globally
- Cachexia contributes to 20-25% of cancer-related deaths, limiting treatment options
The big picture
This grant highlights growing focus on cachexia as a critical unmet need in oncology. With pancreatic cancer projected to become the second leading cause of cancer death in the U.S., metabolic interventions represent a strategic shift from traditional tumor-focused approaches. The $747K award reflects increasing NCI investment in survivorship research, particularly for aggressive cancers with limited treatment options.
What we're watching
- Therapeutic Breakthrough
- Whether STAT3 inhibition can translate to clinical cachexia treatments
- Research Impact
- How this epigenetic approach may apply to other cancer types
- Funding Pipeline
- The pace at which NCI will support similar precision oncology projects
Related topics